3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase EARLY_PHASE1
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
257
Cyclophosphamide
241
Specimen Handling
198
fludarabine
173
Magnetic Resonance Spectroscopy
173
Biopsy
147
Nivolumab
119
Carboplatin
97
Radiotherapy
92
Paclitaxel
85
venetoclax
82
Cisplatin
80
Gemcitabine
79
fludarabine phosphate
78
Injections
68
Ipilimumab
64
Dexamethasone
61
atezolizumab
59
Bevacizumab
58
Cetuximab
57
Radiation
55
Fluorouracil
55
Azacitidine
55
durvalumab
54
Radiosurgery
52
Temozolomide
47
Rituximab
44
Oxaliplatin
44
Irinotecan
43
Docetaxel
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
High-Intensity Focused Ultrasound Ablation
×
1 year
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled